Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02315625
Title	Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	gastrointestinal neuroendocrine tumor neuroendocrine tumor islet cell tumor pancreatic endocrine carcinoma
Therapies	Everolimus Sunitinib
Age Groups:	senior \| adult
Covered Countries	USA